Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,264.23 -42.78 (-0.81%) Dow
39,041.02 -630.02 (-1.59%) Nasdaq
16,722.65 -78.89 (-0.47%) Bitcoin USD
67,307.53 -2,369.52 (-3.40%) CMC Crypto 200
1,461.60 -41.06 (-2.73%)
AMGN Jan 2025 340.000 call
| Previous close | 18.37 |
| Open | 17.00 |
| Bid | 15.95 |
| Ask | 17.50 |
| Strike | 340.00 |
| Expiry date | 2025-01-17 |
| Day's range | 17.00 - 17.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 721 |
ZacksTop Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
